Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
September 26 2018 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Hugh Cole, chief business officer and head of corporate development
at Jounce, will present at the 2018 Cantor Global Healthcare
Conference on Wednesday, October 3, 2018 at 1:40 p.m. ET in New
York, NY.
A live webcast of the presentation will be available by visiting
“Events and Presentations” in the Investors and Media section of
Jounce’s website at www.jouncetx.com. A replay of the webcast will
be archived for 30 days following the presentation.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long lasting
benefits to patients. Through the use of its Translational Science
Platform, Jounce first focuses on specific cell types within tumors
to prioritize targets, and then identifies related biomarkers
designed to match the right immunotherapy to the right patient.
Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody
that binds to and activates ICOS and is currently
conducting the Phase 1/2 ICONIC trial. For more information, please
visit www.jouncetx.com.
Investor Contact: Komal Joshi Jounce
Therapeutics, Inc. (857) 320-2523 kjoshi@jouncetx.com
Media Contact: Gina Nugent The Yates Network
(617) 460-3579 gina@theyatesnetwork.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024